Study evaluates BA.5-bivalent booster against new Omicron sublineages biorxivpreprint utmbhealth Omicron SARSCoV2 COVID19 Booster
By Neha MathurNov 4 2022Reviewed by Aimee Molineux In a recent study posted to the bioRxiv* preprint server, researchers evaluated the efficacy of four doses of parental messenger ribonucleic acid vaccine and a BA.5-bivalent booster against recently emerged Omicron sublineages. Additionally, they determined whether prior infection improved the effect of a booster vaccination.
Previous studies showed that three- or four doses of parental mRNA vaccine did not elicit robust neutralization against BA.4/5, supporting the bivalent vaccine strategy. The newly emerged Omicron sublineages have accumulated additional spike mutations . Thus, it is important to evaluate the effect of vaccination sera against these new sublineages.
The team used three human serum panels with unique vaccination and coronavirus disease 2019 history for the study analyses. The first comprised 25 sera samples taken one to three months after double boosting or four doses of a parental mRNA vaccine . The second panel had 29 sera samples collected one month after receipt of BA.5-bivalent-booster sera .
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Efficacy of booster messenger ribonucleic acid COVID-19 vaccinations against SARS-CoV-2 Omicron variant severityResearchers estimated the effectiveness of monovalent messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC) infection severity outcomes among adults.
Weiterlesen »
Bivalent mRNA booster broadens humoral immunity against SARS-CoV-2 Omicron subvariantsResearchers at Emory University, Stanford University, and the National Institute of Allergy and Infectious Diseases evaluated whether bivalent coronavirus disease 2019 (COVID-19) boosters conferred protection against new Omicron subvariants.
Weiterlesen »
Novel monoclonal antibodies NA8 and NE12 can neutralize most SARS-CoV-2 variants and Omicron subvariantsResearchers generated and characterized two monoclonal antibodies (NA8 and NE12) that target the receptor binding domain of the SARS-CoV-2 spike protein, and exhibit neutralizing activity against major SARS-CoV-2 variants of concern.
Weiterlesen »
SARS-CoV-2 Omicron's newest subvariant BQ.1.1 shows extraordinary immune evasion potential against vaccine seraSARS-CoV-2 Omicron's newest subvariant BQ.1.1 shows extraordinary immune evasion potential against vaccine sera biorxivpreprint BIDMChealth SARSCoV2 COVID19 Omicron Subvariant ImmuneEvasion Vaccine VaccineSera
Weiterlesen »